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Neck–cervical metastasisAbstract Juvenile granulosa cell tumour (JGCT) is a rare tumour arising from the ovarian sex
cord stroma (SCST) and comprising about 5 percent of all granulosa cell tumours. To our knowl-
edge, a cervical metastasis has not been described before.
We report a case of a 19-year-old female who had a left supraclavicular mass with a previous his-
tory of a JGCT in 2010 and an abdominal recurrence in 2011 followed by radiotherapy and
chemotherapy after surgery.
JGCT generally affects young women, can be hormonally active, and has malignant potential.
The diagnosis is made by histopathology after surgical removal, although it should be suspected
when there is a large adnexal tumour along with hyperestrogenism signs. Regional lymph nodes
metastases are rare let alone extra-abdominal ones.
 2015 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction/background
Granulosa cell tumours (GCTs) are rare neoplasms arising
from the sex cord stroma cells of the ovaries. They represent
1.2% of all primary ovarian cancers.1 They can be classified
in two subtypes: the adult (95%) and the juvenile (5%), basedon the clinical and histologic characteristics.2 The first mostly
occurs in middle-aged women (mean age of 50–54 years), with
generally a low degree of tumour cell atypia and mitosis. The
latter generally affects teenagers or women of reproductive
age, making it important to choose the right fertility-sparing
treatment when there is a good long-term prognosis, but there
is a relative high risk of recurrence with long disease-free inter-
vals in between.3
From the histopathological point of view, adult granulosa
cell tumour (AGCT) has round cells with scant cytoplasm
and classic ‘‘coffee-bean” grooved nuclei. They may arrange
themselves in small clusters around a central cavity, forming
the Call-Exner bodies (although the lack of them is not infre-
quent). JGCT has a high proliferative rate and a moderate to
high degree of cell atypia.4 At early stages, these tumours have.
40 M. Al Khalil et al.a good prognosis, but later on the clinical course prognosis is
less favourable with multiple relapses.5
Immunohistochemical staining (IHC) is helpful for differ-
ential diagnosis, which includes mainly endometrial stromal
sarcoma, undifferentiated carcinoma, and small cell carci-
noma.6 In 1989, Lappo¨hn et al. reported high serum levels
of inhibin in patients with GCT.7 Inhibin is a peptide hor-
mone produced by granulosa cells in the ovarian follicles
with two subtypes, inhibin A (produced by the dominant
follicle) and inhibin B (produced by the developing follicles).
They have been found to be a more reliable marker for
GCT than estradiol.7 They create a negative feedback
against the follicle-stimulating hormone (FSH) concealed in
the anterior part of the pituitary gland. Serum inhibin B
seems to be the predominant form of inhibin secreted by
granulosa cell tumours and appears to reflect disease status
more accurately than inhibin A.5 However, it is not com-
pletely specific for an ovarian sex cord tumour as sex cord
stromal differentiation can be seen in other neoplasms, like
ovarian endometrioid tumours and metastatic carcinomas
to the ovary.8
Clinically, GCT presents as an asymptomatic slow-growing
abdominal mass. Hyperestrogenism symptoms such as breast
tenderness, postmenopausal bleeding, menstrual abnormali-
ties, and in children, sexual precocity, are often common.2
Generally sporadic, they can also be related with other clinical
findings: in the presence of hemangiomas to Maffucci syn-
drome, or in the company of enchondromatosis, and Ollier’s
disease. GCT is sometimes associated with hemangiomas and
ambiguous genitalia with leprechaunism.9
Treatment guidelines for GCT suggest surgical staging
according to the FIGO (International Federation of Gynecol-
ogy and Obstetrics)8 system. If the patient has fulfilled her fer-
tility desires, abdominal hysterectomy and bilateral salpingo-
oophorectomy are generally recommended with or without
pelvic and para-aortic lymphadenectomy, omentectomy, peri-
toneal biopsy, and removal of any suspicious lesions.3 In early
stages preservation of the healthy ovary and the uterus with an
endometrial biopsy may be performed for young patients who
desire to maintain fertility. Because of the slow growth of the
tumour and the high rate of recurrence in advanced stages, sec-
ondary debulking may be an option and can improve the
survival.5
Until now, there is no standardized treatment for adjuvant
therapy. General consensus recommends no further treatment
besides surgery for Stage IA. National Comprehensive Cancer
Network (NCCN) guidelines advise platinum-based
chemotherapy and or radiotherapy for stages II to IV. The
most important prognostic factor is the disease stage and resid-
ual tumour.2,8Figure 1 PET scan with FDG showing a pathological uptake in
the right supraclavicular area.2. Case presentation
We present a 19-year-old Egyptian female who came to our
Head and Neck Multidisciplinary team meeting in Hamad
Medical Corporation (Doha, Qatar) for evaluation of a left
supraclavicular mass that could be related to a JGCT diagno-
sis and was initially treated in June 2010.
There was no remarkable medical history besides thrombo-
cytopenia of 51,000 platelets when she was 6 years old that
recovered spontaneously with no specific treatment.She approached the gynaecology clinic with abdominal
pain and excessive menstrual bleeding where an abdominal
mass was detected related to the right ovary. The patient
underwent a right salpingo-oophorectomy, omentectomy,
and a peritoneal biopsy that reported negative. Histopathol-
ogy reported a JGCT localized in the right ovary. She received
adjuvant chemotherapy in September 2010: 5 cycles per week -
 5 weeks of carboplatin. The patient recovered from treat-
ment but in July 2011 she presented again with abdominal
pain and continuous vomiting, and a retroperitoneal mass
between the lower segments of the aorta and the inferior vena
cava was noticed, suggesting a recurrence. This time, a midline
laparotomy was done with bilateral pelvic, paraaortic, and
lower vena cava lymphadenectomy that showed a metastatic
JGCT tumour. Peritoneal wash was again negative for malig-
nancy. Postoperative radiotherapy at a dose of 45 Gy (25 ses-
sions  1.8 Gy) was given to the lower paraaortic region.
In May 2013, the patient returned to the hospital with
night sweats and a left moderately painful supraclavicular
mass of three months of duration. Ultrasound showed multi-
ple left lower jugular adenopathies, the biggest measuring
19.7  14.8 mms and showing a hypoechoic pattern.
A PET scan with F-18 fluorodeoxyglucose (FDG) showed a
pathological ring-like uptake in the lower left parajugular area
of approximately 2  2.5 cm proximal to the left internal jugu-
lar vein joining the left subclavian vein (Fig. 1). Excisional
biopsy was done but in November 2013, another ovoid mass
was noted at the root of the neck on the same side, posterior
to the carotid sheath, displacing vascular structures mildly
anteriorly. Again, a biopsy was taken.
Histologic examination of the first mass showed a replace-
ment of lymphoid tissue by a malignant neoplasm with mor-
phologic and immunohistochemical features similar to the
earlier ovarian tumour (Figs. 2 and 3). The neoplasm shows
a solid nodular configuration with focal trabeculae and abun-
dant necrosis. The cells are medium to large size, focally hav-
ing a leutinized appearance. There was marked
hyperchromasia and frequent mitosis was identified.
Immunoperoxidase stains were performed with appropriate
controls which showed the tumour cells to stain with CD99
and WT-1. The cells were negative for carcinoma markers
including cytokeratins (CKs) and epithelial membrane antigen
(EMA). Germ cell markers including PLAP and CD117 were
also negative, as were S-100 and LCA, excluding melanoma
and lymphoma. Although no staining was noted with inhibin,
the morphologic features and immunoprofile were most com-
patible with a juvenile granulosa cell tumour. The second
biopsy did not show significant differences from the first.
During the multidisciplinary tumour meeting, after the
patient refused chemotherapy, it was decided to give adjuvant
Figure 2 Histopathological photomicrograph showing replace-
ment of lymphoid tissue by a malignant neoplasm with morpho-
logic and immunohistochemical features similar to the earlier
ovarian tumour. H&E 100.
Figure 3 Histopathological photomicrograph showing replace-
ment of lymphoid tissue by a malignant neoplasm with morpho-
logic and immunohistochemical features similar to the earlier
ovarian tumour. H&E 200.
Neck metastasis of a juvenile granulosa cell tumour 41radiotherapy since there were no signs of disease activity else-
where by PET/CT scan after surgery. 60 Gy to the grossly
enlarged nodes, 54 Gy (30 fractions) to the lower neck nodal
station and surgical bed and 50.4 Gy to the adjacent unin-
volved region. Radiotherapy was delivered in 30 fractions
using Simultaneous integrated boost (SIB) technique. This
study was approved by Hamad Medical Corporation Research
Department.
A waiver of informed consent was obtained.
3. Discussion
GCTs tend to have an indolent growth, especially during the
first stage, and recurrences appear late (a mean of 4–6 years
after initial diagnosis).5 Lymph node metastases are rare and
therefore some surgeons omit paraaortic lymphadenectomy
during the surgical staging for these tumours, following these
patients closely afterwards. Most authors suggest that unilat-
eral salpingo-oophorectomy and uterine preservation may pro-
vide a similar survival rate to other more aggressive treatmentsaccording to recent papers.6,10,11 Zhang et al. compares 132
patients with sex cord stromal tumours (SCSTs) younger than
50 diagnosed with stage I disease: 61 (46%) underwent stan-
dard surgical treatment including hysterectomy, and 71
(54%) had a uterine-sparing procedure. The prognosis for
both groups seems to be good with equivalent 5-year survival
rates of 97% and 98% (p= 0.61).10 Removal of lymph nodes
during the initial surgery might not predict the pattern of
recurrence or have a clear benefit to the patient. Complete
removal of the primary tumour seems to be the most impor-
tant prognostic factor.2
Our patient underwent two excisional biopsies of a left
supraclavicular metastatic node in June and November 2013
without any complications. Following the second surgery,
she received radiotherapy to the surgical bed and adjacent
lymph node regions.
4. Conclusion
JGCT is a rare ovarian tumour that usually spreads by direct
extension and through the lymph nodes. The decision for the
type of surgical excision at its primary site is debatable due
to the few number of cases and follow-ups reported in the lit-
erature, but fertility sparing surgery seems to be the treatment
of choice in young patients in the majority of the cases
reviewed in this study. A distant cervical metastasis is an
adverse situation that has not been described in the literature
until now.
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